Myasthenia Gravis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Clinical Trials
• Forums

CANbridge Pharmaceuticals Announces Orphan Drug Designation Granted to CAN 106 for the Treatment of Myasthenia Gravis
Beijing, China; Burlington, Mass., November 15, 2022— CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 15, 2022 Category: Pharmaceuticals Source Type: clinical trials

The ME & MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
Condition:   Myasthenia Gravis Intervention:   Device: ME&MG  mobile application Sponsor:   Ad scientiam Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2022 Category: Research Source Type: clinical trials